ARWR has given back 47% from the August SHASTA high, even as management swapped "we are in the education business" for "full steam ahead" — the entire thesis now hinges on a funnel, not a prescription count.
ARWR · Earnings Call · 2026-11-12
A stock that sold the news it wanted
Arrowhead's fiscal 2026 call landed on 2026-11-12, and by then the equity had already voted. The shares peaked at $89.59 on 2026-08-04 — the day the SHASTA-3 and SHASTA-4 topline data crossed the wire — and the recent tape reads brutally: down 43.9% over 90 trading days, a 47.4% drawdown from that peak, with the damage concentrated in a single ten-week leg that took a sixth of the value out before the dump. This is not a case of bad news arriving; it is a market marking down the conversion of good news into revenue.
And that isolation matters. The market's curated themes right now are elsewhere entirely — the global tape is a referendum on AI infrastructure, memory pricing, and tariff mitigation, with data center AI and high bandwidth memory hoovering up capital in both directions across the 30-, 90- and 360-day windows. Nothing in the market trajectory is voting on cardiometabolic rare disease. Arrowhead's own top-ranking themes are almost entirely company-unique — SHTG launch, prescriber base, rapid launch, FCS market — which means there is no wave to ride here, only execution. No sector bid is going to rescue a launch that stalls.
The language changed before the launch did
Rightly or not, the clearest signal on this call was rhetorical. Three months ago, with the SHASTA data freshly in hand, the CEO described the coming market in explicitly patient terms:
this is going to be a relatively slow ramp because this is a brand-new market. We are in the education business.
On Tuesday, the same CEO opened the Q&A by declaring that “we are full steam ahead towards a rapid launch in SHTG” — Christopher Anzalone, President · 2026-11-12 — and dismissed the closest available read-across, Ionis's soft olezarsen launch, as "some missteps in communication, some missteps in commercial execution" that Arrowhead does not expect to repeat.
That is a confident answer to a question that deserves a nervous one. The prior call also gave a specific weekly run-rate benchmark — 20 to 30 new prescriptions — which has since been revised to roughly 50 to 60 a week, so demand is real. What has never been quantified, on this call or any prior one, is the lag between script and paid shipment.
Management effectively pre-empted the scrutiny by redefining the scoreboard. Instead of revenue, investors were handed three leading indicators: new-to-brand prescriptions, distinct prescribers, and covered lives. That is a defensible framing for a launch's first quarters — but it is also a framing that arrives precisely when the comparable launch is disappointing. The CEO was candid that “we're not walking away from revenue… our point here is that in the early stages of the launch, that may not tell the entire story” — Christopher Anzalone, President · 2026-11-12, and equally candid that a formal SHTG outlook is simply not on the table: “we don't even have a PDUFA date yet, much less a label.” — Christopher Anzalone, President · 2026-11-12
What the funnel actually looks like
The FCS numbers are real but small. Fiscal 2026 net product revenue was approximately $6.6 million — against total revenue of $450.8 million, which was dominated by partnership recognition from Sarepta, Novartis, Madrigal and Sanofi. By September 30 there were 950 new-to-brand prescriptions, up 63% quarter on quarter, since grown past 1,250; prescribers went from over 640 to over 860; more than 160 million U.S. lives sit under published payer policies. The choke point is the middle of the funnel, which the CEO described as “the slow piece of this has been what we call the middle of the funnel” — Christopher Anzalone, President · 2026-11-12 — benefit verification, prior authorisation, and the reimbursement navigator team's work.
That is why the pricing decision is the most consequential thing on this call, and why it is a reversal. In August 2025 the CEO told investors that for SHTG “we certainly would expect that to be a lower-priced drug than FCS” — Christopher R. Anzalone, President and CEO · 2025-08-08; in April 2026 the WAC was cut from $60,000 to $45,000 with the insistence that the cut “had nothing to do with any pushback from the payers” — Dr. Christopher Anzalone, President and CEO · 2026-05-07. Now the plan is one price across both indications, held flat into a market three orders of magnitude larger. Andy Davis reports no pushback in pre-approval information exchange discussions, which is encouraging — but a held price is a bet that payer friction will be navigated, not repriced away.
The money side actually improved
Strip out the launch debate and this was a decently clean quarter. The Sixth Street refinancing replaced a 15%-coupon facility with a $400 million term loan at SOFR plus 5.5%, negotiated a $68 million discount to the retirement value, pushed maturity to November 2031, and removed the cash sweeps. Add $700 million of 0% converts due 2032 and there are no principal payments before late 2031 — a genuine structural fix, executed while the equity was falling.
Cash and investments closed the year near $1.2 billion after absorbing a $215 million priority review voucher purchase that is now redundant: STAR entry means the voucher is sellable, and publicly announced comps of $180–220 million imply a pro forma balance near $1.4 billion. Against roughly $272 million of annual operating cash use, that is real runway.
The cost line is the other half of the story. R&D reached $739 million for the year and SG&A doubled to $202 million, lifting the operating base ahead of revenue. At 17.2x trailing revenue, the equity is already priced for a successful conversion — which is precisely why a 47% drawdown followed the data rather than preceded it.
The option value nobody is paying for
Beyond Redemplo sits a pipeline the tape is currently ignoring: CNS targets reached by subcutaneous injection, where ARO-MAPT drove mean CSF total tau down 73% at day 105; the bridging biomarkers of p-tau 181/217 and tau PET that will decide whether Alzheimer's or the primary tauopathies get pursued first; ARO-DIMER-PA's dual PCSK9/ApoC3 knockdown with 89% and 95% maximal reduction; zodasiran's fully enrolled Yosemite HoFH study of 70 patients. Management was explicit that U.S. SHTG is not for sale — “at least in the United States, we have no appetite in partnering there” — Christopher Anzalone, President · 2026-11-12 — leaving obesity and NASH as the likelier deal ground.
So the debate is narrow. Nothing about the science broke this week; the stock broke because the market moved from pricing a data event to pricing an execution event. The next twelve months supply the answer in three numbers: prescriptions, prescribers, covered lives — and, eventually, the paid shipments they are supposed to become.